These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 32461076)

  • 21. Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations.
    Alhalaweh A; Bergström CAS; Taylor LS
    J Control Release; 2016 May; 229():172-182. PubMed ID: 27006280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.
    Miller DA; Keen JM; Brough C; Ellenberger DJ; Cisneros M; Williams RO; McGinity JW
    J Pharm Pharmacol; 2016 May; 68(5):678-91. PubMed ID: 26454138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relevance of co-amorphous formulations to develop supersaturated dosage forms: In-vitro, and ex-vivo investigation of Ritonavir-Lopinavir co-amorphous materials.
    Sai Krishna Anand V; Sakhare SD; Navya Sree KS; Nair AR; Raghava Varma K; Gourishetti K; Dengale SJ
    Eur J Pharm Sci; 2018 Oct; 123():124-134. PubMed ID: 30048798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a three compartment in vitro gastrointestinal simulator dissolution apparatus to predict in vivo dissolution.
    Takeuchi S; Tsume Y; Amidon GE; Amidon GL
    J Pharm Sci; 2014 Nov; 103(11):3416-3422. PubMed ID: 25251982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
    Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
    Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism for the Reduced Dissolution of Ritonavir Tablets by Sodium Lauryl Sulfate.
    Guo Y; Wang C; Dun J; Du L; Hawley M; Sun CC
    J Pharm Sci; 2019 Jan; 108(1):516-524. PubMed ID: 30389564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
    Franek F; Holm P; Larsen F; Steffansen B
    Int J Pharm; 2014 Jan; 461(1-2):419-26. PubMed ID: 24342711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrointestinal transfer: in vivo evaluation and implementation in in vitro and in silico predictive tools.
    Hens B; Brouwers J; Anneveld B; Corsetti M; Symillides M; Vertzoni M; Reppas C; Turner DB; Augustijns P
    Eur J Pharm Sci; 2014 Oct; 63():233-42. PubMed ID: 25064697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs.
    Hens B; Tsume Y; Bermejo M; Paixao P; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Dickens J; Shedden K; Wen B; Wysocki J; Loebenberg R; Lee A; Frances A; Amidon G; Yu A; Benninghoff G; Salehi N; Talattof A; Sun D; Amidon GL
    Mol Pharm; 2017 Dec; 14(12):4281-4294. PubMed ID: 28737409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion.
    Hens B; Corsetti M; Brouwers J; Augustijns P
    J Pharm Sci; 2016 Sep; 105(9):2904-2912. PubMed ID: 27178739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug - Drug Interaction Studies.
    Litou C; Vertzoni M; Goumas C; Vasdekis V; Xu W; Kesisoglou F; Reppas C
    Pharm Res; 2016 Jun; 33(6):1399-412. PubMed ID: 26975361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of an Artificial Stomach-Duodenum Reduced Gastric pH Dog Model for Formulation Principle Assessment and Mechanistic Performance Understanding.
    Lee CM; Luner PE; Locke K; Briggs K
    J Pharm Sci; 2017 Aug; 106(8):1987-1997. PubMed ID: 28238897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration.
    Kourentas A; Vertzoni M; Barmpatsalou V; Augustijns P; Beato S; Butler J; Holm R; Ouwerkerk N; Rosenberg J; Tajiri T; Tannergren C; Symillides M; Reppas C
    AAPS J; 2018 May; 20(4):71. PubMed ID: 29797293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enabling thermal processing of ritonavir-polyvinyl alcohol amorphous solid dispersions by KinetiSol® Dispersing.
    LaFountaine JS; Jermain SV; Prasad LK; Brough C; Miller DA; Lubda D; McGinity JW; Williams RO
    Eur J Pharm Biopharm; 2016 Apr; 101():72-81. PubMed ID: 26861929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Sparkling Water on Intraluminal Formulation Behavior and Systemic Drug Performance.
    Van Den Abeele J; Brouwers J; Deloose E; Tack J; Augustijns P
    J Pharm Sci; 2017 Sep; 106(9):2472-2482. PubMed ID: 28392455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions.
    Law D; Krill SL; Schmitt EA; Fort JJ; Qiu Y; Wang W; Porter WR
    J Pharm Sci; 2001 Aug; 90(8):1015-25. PubMed ID: 11536205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the usefulness of compendial setups and tiny-TIM system in evaluating the in vivo performance of oral drug products with various release profiles in the fasted state: Case example sodium salt of A6197.
    Schilderink R; Protopappa M; Fleth-James J; Vertzoni M; Schaefer K; Havenaar R; Kulla I; Metzger M; Reppas C
    Eur J Pharm Biopharm; 2020 Apr; 149():154-162. PubMed ID: 32057905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastrointestinal behavior of itraconazole in humans - Part 1: Supersaturation from a solid dispersion and a cyclodextrin-based solution.
    Brouwers J; Geboers S; Mols R; Tack J; Augustijns P
    Int J Pharm; 2017 Jun; 525(1):211-217. PubMed ID: 28414135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective Laser Sintering 3-Dimensional Printing as a Single Step Process to Prepare Amorphous Solid Dispersion Dosage Forms for Improved Solubility and Dissolution Rate.
    Davis DA; Thakkar R; Su Y; Williams RO; Maniruzzaman M
    J Pharm Sci; 2021 Apr; 110(4):1432-1443. PubMed ID: 33227241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT.
    Kourentas A; Vertzoni M; Symillides M; Hens B; Brouwers J; Augustijns P; Reppas C
    Int J Pharm; 2016 Dec; 515(1-2):352-358. PubMed ID: 27732895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.